CCK8 assays showed that MCT1 knockdown resulted in a decrease in viable RB cells (Fig. 4B), while AZD3965 treatment caused a dose-dependent reduction in tumor cell viability (Fig. 4C). Here, SLC16A1 is linked to neoplasm.